Ajanta Pharma launches generic ADHD treatment drug in US

Drug firm Ajanta Pharma today said it has launched generic Clonidine Hydrochloride extended release tablets in the American market after receiving the US health regulator's nod.
The company has launched the tablets in the strength of 0.1 mg in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc, Ajanta Pharma said in a BSE filing.
The product is a generic version of Concordia Pharmaceuticals Inc's Kapvay tablets, it added.
The tablets are a part of the growing portfolio of products that the company has developed for the US market, Ajanta Pharma said.
Clonidine Hydrochloride extended release tablets are used for the treatment of attention deficit hyperactivity disorder (ADHD).

The company currently has 22 final approvals for its abbreviated new drug applications (ANDAs) from the United States Food and Drug Administration (USFDA). It also has two tentative approvals and 15 ANDAs under review with the regulator, Ajanta Pharma said.
Till date, the drug maker has launched 16 products in the US market.
Shares of Ajanta Pharma today closed 0.54 per cent higher at Rs 1,343.35 per scrip on BSE today.